RSC-BMCS/SCI Targeting Protein Degradation 4
Event
RSC-BMCS/SCI Targeting Protein Degradation 4
Dates
15 October – 16 October 2024
Place
Cranfield University, UK
Important links
Twitter hashtag – #ProtDeg24
Please click here for main conference website
Synopsis
One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). In 2021, the Targeted Protein Degradation Market size was valued at USD 400.5 million and is poised to grow from USD 507.0 million in 2022 to USD 3,300.0 million by 2030 and so has attracted interest from academia, non-profit organisations through to CROs and small and large pharma.
This multidisciplinary meeting aims to present the latest developments in the design, biology, chemistry and ADME in TPD within the general themes of PROTACS (including non-oncology targets), Molecular Glues and non-PROTAC degraders. We aim to highlight the newest in enabling technologies such as computational techniques, Direct to Biology, HT synthesis (click, photochemistry etc) and structural biology methods.
Who should attend
The meeting aims is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.
Call for Abstracts
Submissions for oral and/or poster presentations are welcomed around the conference general themes. Abstracts should be maximum 300 words indicating title, authors, institution and preference for presentation option (Oral presentation and/or Poster) and sent to conferences@soci.org with the subject line “Targeting Protein Degradation 2024 – abstract submission”. Presentation slots are inevitably limited and will be allocated to achieve a balanced programme. Prizes will be awarded for the best presentation and poster.
Deadline for oral presentations – Friday 31 May 2024 (decisions by end of June)
Deadline for poster presentations – Friday 30 August 2024
Programme
Tuesday 15th October 2024
09.45 | Registration |
---|---|
10.25 | Opening Remarks |
10.30 | Plenary lecture: Gazing into the crystal ball - what have we learnt and where does TPD research need to go next? Ian Churcher, Janus Drug Discovery |
11.10 | Discovery of Novel Small Molecules Binders of Soluble Mutant HTT and Derivatization into PROTACs Geoffrey Schwertz, UCB |
11.35 | Discovery of BclxL protein degraders for overcoming cancer resistance Jim Sheppeck, AZ |
12.00 | Targeting cancer with panKRAS degraders Vesna Vetma, Centre for Targeted Protein Degradation, Dundee |
12.25 | Lunch |
13.30 | Photocatalysis enabled One-Pot PROTAC Library Synthesis Jacqueline Bitai, Boehringer Ingelheim |
13.55 | Exploring the Pharmacokinetics of PROTACs: A Focus on Solubility and Metabolic Stability Gabriele Cruciani, University of Perugia |
14.20 | CRBN-midi: expanding the toolbox for structural and biophysical characterization of protein degraders Alena Kroupova, Centre for Targeted Protein Degradation, Dundee |
14.45 | Leveraging XChem Crystallographic Fragment Screening and Chemist-Assisted Robotics for Silent Hotspot Mapping and Rapid Fragment Expansion Thomas Webb, Centre for Targeted Protein Degradation, Dundee |
15.10 | Refreshments and Exhibition |
15.40 | Making it stick – how can we convert inhibitors into molecular glue degraders? Ben Bellenie, ICR Centre for Protein Degradation |
16.20 | Identification, optimization and characterization of Cyclin K molecular glue degraders Douglas Thomson, Proxygen |
16.45 | Degradation of BRD9 by a novel targeted glue Andrea Testa, Amphista Therapeutics |
17.10 | Flash Poster Presentations |
17.30 | Poster presentations and networking drinks (till 18.10) |
19.00 | Conference Dinner |
Wednesday 16th October 2024
09.00 | Registration and Exhibition |
---|---|
09.15 | Plenary lecture: Molecular mechanisms and rational design of protein degraders Alessio Ciulli, Centre for Targeted Protein Degradation, Dundee |
09.55 | Development and Application of Direct-to-Biology for High-Throughput PROTAC Synthesis and Testing Rob Law, GSK |
10.20 | RSC BMCS Hall of Fame Award and Lecture: A career doing STUFF Mike Hann, GSK |
11.00 | Refreshments and exhibition |
11.30 | Enabling targeted protein degradation in bacteria Ester Morreale, Crick Institute |
11.55 | Development of the ULK1-Recruiting Chimeras (ULKRECs) to enable proximity-induced and ULK1-dependent degradation of “undruggable” targets David Selwood, University College London |
12.20 | Structural Insights into PROTAC Handle Development for the Cullin-2 Substrate Adaptor KLHDC2 Melissa Sweeney, University of Oxford |
12.45 | Lunch |
13.45 | Plenary lecture: Targeting chromatin regulatory proteins with therapeutic degraders Danette Daniels, Foghorn Therapeutics |
14.25 | TBC |
14.55 | PROTAC-based approach to develop broad-spectrum antiviral agents triggering the proteolysis of the major viral protease Alessia De Santis, University of Florence |
15.20 | Activin Receptor-like Kinase 2 Degradation as a Novel Therapeutic Strategy Towards the Treatment of Diffuse Intrinsic Pontine Glioma Daniel Webb, Charles River Laboratories |
15.45 | Closing Remarks |
Exhibitors/Sponsors
For further information and prices, please email conferences@soci.org.
Organising Committee
Sean Bew, UEA
Stuart Cameron, Concept life sciences
Nicola Chessum, Boehringer-Ingelheim
Katherine Jones, Charles River
Suzanne O’Connor, University of Dundee
Hannah Woodward, MSD